Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, exclusive license to TAPI’s innovative forms of resmetirom active pharmaceutical

#SGMT Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SGMT/sagimet-biosci...

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference Sagimet Biosciences (Nasdaq: SGMT) will present a poster at the 10th Annual MASH-TAG Conference held January 8-10, 2026 in Park City, Utah.The poster reports a secondary analysis from the Phase 2b FASCINATE-2 trial showing that denifanstat elicited a significant ≥2-stage fibrosis improvement in F3 MASH patients and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients. Presenting author is Rohit Loomba, M.D., M.H.Sc. Poster number MASHTAG.2026.A23 will be presented on Saturday, January 10, 2026 at The Chateaux Deer Valley.

#SGMT Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

www.stocktitan.net/news/SGMT/sagimet-biosci...

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination The combination of denifanstat and resmetirom was generally well-tolerated Pharmacokinetic (PK) results support further development of the combination A Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025

#SGMT Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

www.stocktitan.net/news/SGMT/sagimet-biosci...

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Sagimet Biosciences (Nasdaq: SGMT) reported Q3 2025 corporate updates and financials on November 13, 2025. Key clinical milestones include an ongoing Phase 1 PK trial of a once-daily combination of denifanstat and resmetirom (≈40 healthy adults) with topline data expected in 1H 2026, and an ongoing first-in-human Phase 1 trial of FASN inhibitor TVB-3567 for acne. Partner Ascletis completed a pre-NDA consultation with China’s NMPA and plans an NDA submission for denifanstat for moderate-to-severe acne after a 480-patient Phase 3 trial that met all efficacy endpoints. Financials: $125.5M cash and marketable securities; nine-month net loss $41.5M.

#SGMT Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SGMT/sagimet-biosci...

#SGMT Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

www.stocktitan.net/news/SGMT/sagimet-biosci...

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration Ascletis (HKEX:1672) completed a pre-NDA consultation with China NMPA for denifanstat (ASC40) for moderate-to-severe acne vulgaris, initiated in June 2025 and completed in October 2025, and plans to submit an NDA soon.Ascletis completed Phase II (NCT05104125) and Phase III (NCT06192264) studies; the Phase III met all primary, key secondary and secondary efficacy endpoints (ITT) and showed statistically significant improvement versus placebo. Denifanstat demonstrated a favorable safety and tolerability profile: all related TEAEs were Grade 1–2, with no related Grade 3–4 TEAEs, SAEs, permanent discontinuations, or withdrawals. Phase III results were presented at EADV Congress on Sept 17, 2025. Ascletis holds exclusive Greater China rights via license from Sagimet (Nasdaq: SGMT).

#SGMT Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

www.stocktitan.net/news/SGMT/ascletis-compl...

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Sagimet Biosciences (NASDAQ:SGMT) reported significant progress in Q2 2025, highlighted by positive Phase 3 trial results for denifanstat in acne treatment through its partner Ascletis in China. The trial met all primary endpoints, showing 33.2% treatment success vs. 14.6% for placebo.The company initiated a Phase 1 trial for TVB-3567, another FASN inhibitor for acne treatment in the U.S. Additionally, Sagimet plans to start a Phase 1 trial evaluating denifanstat combined with resmetirom for MASH treatment in 2H 2025. As of June 30, 2025, the company reported $135.5 million in cash and equivalents, with a net loss of $10.4 million for Q2 2025.

#SGMT Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SGMT/sagimet-biosci...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu Jun 12th - #SOAR #RSLS #UUUU #UEC #SGMT #SERA #RGTI #QUBT #NVTS #NMAX #MGNX #KULR #EVH #DAWN #CGTL #EQX #APLD #AMPX #ALLO #AI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Jun 4th - #PTON #STSS #VLRS #UUUU #UEC #TRMD #SPCB #SGMT #SEDG #RCAT #QUBT #OMCL #MULN #EVH #DDD #DBVT #BTCS #BORR #BMGL #FSM - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis Sagimet Biosciences (NASDAQ: SGMT) announced positive Phase 3 trial results for denifanstat (ASC40) in treating moderate-to-severe acne, conducted by partner Ascletis in China. The trial met all primary and secondary endpoints, with denifanstat showing significant improvements over placebo. The drug achieved 33.2% treatment success rate versus 14.6% for placebo, and demonstrated substantial reductions in total lesion count (-57.4% vs -35.4%), inflammatory lesions (-63.5% vs -43.2%), and non-inflammatory lesions (-51.9% vs -28.9%). The oral FASN inhibitor was well-tolerated with mild to moderate side effects, primarily dry skin (6.3%) and dry eye (5.9%). Ascletis plans to submit for approval in China. Additionally, Sagimet has initiated a Phase 1 trial for TVB-3567, a second FASN inhibitor, for acne treatment in the US market.

#SGMT Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

www.stocktitan.net/news/SGMT/sagimet-biosci...

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints Ascletis announces successful Phase III trial results for Denifanstat (ASC40), a first-in-class oral FASN inhibitor for acne treatment. The trial met all endpoints with 33.2% treatment success vs 14.6% for placebo. Denifanstat showed superior efficacy compared to FDA-approved treatments: 98% more effective than sarecycline, 178% more effective than doxycycline, and 60% more effective than clascoterone cream in placebo-adjusted treatment success. The drug demonstrated significant reductions in total lesion count (57.4%), inflammatory lesions (63.5%), and non-inflammatory lesions (51.9%). With a favorable safety profile and only mild to moderate adverse events, Denifanstat's unique mechanism directly targets sebum overproduction, a root cause of acne. The once-daily oral treatment offers potential advantages over topical treatments, which suffer from 30-40% non-adherence rates.

#SGMT Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

www.stocktitan.net/news/SGMT/ascletis-annou...

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates Sagimet Biosciences (NASDAQ: SGMT) reported Q1 2025 financial results and provided corporate updates. The company plans to initiate a Phase 1 clinical trial in 2H 2025 to evaluate the combination of denifanstat and resmetirom, with data expected in 1H 2026. Pre-clinical data presented at EASL 2024 showed synergistic effects of combining FASN inhibitor with resmetirom, demonstrating 80% improvement in histological improvement compared to 33% and 25% for individual therapies. The company completed End-of-Phase 2 FDA interactions for denifanstat in MASH but requires additional funding before initiating Phase 3 trials. Financial highlights include cash position of $144.6 million, R&D expenses of $15.3 million, and a net loss of $18.2 million for Q1 2025.

#SGMT Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SGMT/sagimet-biosci...

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates Sagimet Biosciences (SGMT) reported its full year 2024 financial results and corporate updates. The company achieved significant milestones, including the initiation of its Phase 3 denifanstat program for MASH treatment, with patient screening expected in 1H 2025. The FDA granted Breakthrough Therapy designation for denifanstat following successful Phase 2b FASCINATE-2 results.Key financial highlights:Cash position of $158.7 million as of December 31, 2024R&D expenses increased to $38.4 million in 2024 from $19.8 million in 2023Net loss widened to $45.6 million in 2024 from $27.9 million in 2023The company received IND clearance for TVB-3567, a second FASN inhibitor for acne treatment. The Phase 3 program includes two trials: FASCINATE-3 for F2/F3 MASH patients and FASCINIT for MASLD/MASH patients, with a minimum of 1,800 patients expected to receive denifanstat.

#SGMT Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SGMT/sagimet-biosci...

FDA Clears Groundbreaking Acne Drug: Sagimet's New FASN Inhibitor Targets 50M Patient Market Novel FASN inhibitor TVB-3567 targets sebum production in acne treatment. Building on successful Phase 2 data, Sagimet expands into $50M+ dermatology market opportunity.

#SGMT Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

www.stocktitan.net/news/SGMT/sagimet-biosci...

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, has announced an oral presentation on denifanstat’s effect on triglycerides and LDL-cholesterol in advanced fibrosis patients. This presentation will be delivered at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium, held from February 23-26, 2025, in Banff, Canada.The presentation will feature lipidomic data from a post-hoc analysis of the Phase 2b FASCINATE-2 trial of denifanstat in MASH (Metabolic Associated Steatohepatitis). The title of the presentation is: Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study. It will be presented by Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences, during the Symposia Spotlight: Emerging Mechanisms session on Wednesday, February 26, 2025, at 3:00 PM MST, at the Fairmont Banff Springs, Banff, AB, Canada.

#SGMT Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

www.stocktitan.net/news/SGMT/sagimet-biosci...

News; ( NASDAQ: #SGMT ) When (SGMT) Moves Investors should Listen

News; ( NASDAQ: #SGMT ) Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

Sagimet to Present Breakthrough MASH Treatment Data at MASH-TAG Conference 2025 Sagimet Biosciences will showcase denifanstat's unique mechanism and Phase 2b success for liver fibrosis treatment at the prestigious MASH-TAG Conference in Utah.

#SGMT Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

www.stocktitan.net/news/SGMT/sagimet-biosci...

Just In: ( NASDAQ: #SGMT ) Outperform Recommendation Issued On SGMT By Oppenheimer

#StockMarket #News

JUST IN: ( NASDAQ: #SGMT ) Expected earnings - Sagimet Biosciences Inc.

#StockMarket #News

NEWS: ( NASDAQ: #SGMT ) Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

#StockMarket #News

#SGMT Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/SGMT/sagimet-biosci...

#SGMT Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

www.stocktitan.net/news/SGMT/sagimet-biosci...

#SGMT Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SGMT/sagimet-biosci...